SCHEMBL6410201

SCHEMBL6410201

CN1C(=O)c2ccccc2C(C(=O)Nc2ccncc2)C1c1cc(C(F)(F)F)cc(C(F)(F)F)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.52
NPC1 O15118 1/20 0.51
ALDH1A1 P00352 3/20 0.47
TSHR P16473 1/20 0.47
HSD17B10 Q99714 4/20 0.46
LMNA P02545 1/20 0.46
MAPT P10636 2/20 0.46
KDM4E B2RXH2 1/20 0.46
CYP3A4 P08684 2/20 0.45
CYP2C9 P11712 2/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
L3MBTL1 Q9Y468 2/20 0.43
CYP1A2 P05177 1/20 0.42
FFAR1 O14842 1/20 0.41
HTT P42858 1/20 0.41
GLA P06280 1/20 0.41
CASP1 P29466 1/20 0.41
TRPM8 Q7Z2W7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6413435 0.90 GAA (0.52) GAANPC1ALDH1A1TSHRHSD17B10
SCHEMBL6410788 0.89 GAA (0.51) GAANPC1ALDH1A1TSHRHSD17B10
SCHEMBL6410777 0.87 GAA (0.48) GAANPC1ALDH1A1TSHRHSD17B10
SCHEMBL6414250 0.87 TSHR (0.49) GAANPC1ALDH1A1TSHRHSD17B10
SCHEMBL6412806 0.86 TSHR (0.46) GAANPC1ALDH1A1TSHRHSD17B10
SCHEMBL6410227 0.86 HSD17B10 (0.56) GAAALDH1A1TSHRHSD17B10LMNA
SCHEMBL6413221 0.86 CYP1A2 (0.55) GAANPC1ALDH1A1TSHRHSD17B10
SCHEMBL6419719 0.86 HSD17B10 (0.50) GAANPC1ALDH1A1TSHRHSD17B10
SCHEMBL6411959 0.85 CYP2C9 (0.51) GAANPC1ALDH1A1TSHRHSD17B10
SCHEMBL6417863 0.84 HSD17B10 (0.49) GAANPC1ALDH1A1TSHRHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US claimed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO claimed
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis AXYS PHARMACEUTICALS, INC. (US) 2005-06-09 US disclosed
WO-2004004727-A1 3,4-DIHYDROISOQUINOLIN-1-ONE DERIVATIVES AS INDUCERS OF APOPTOSIS AXYS PHARMACEUTICALS, INC. (US) 2004-01-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124614-A1 3,4-Dihydroisoquinolin-1-one derivatives as inducers of apoptosis CASP3, BAX, BAD GAA 2485/4885NPC1 1504/4885ALDH1A1 1368/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.